Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022:2547:95-140.
doi: 10.1007/978-1-0716-2573-6_5.

Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity

Eleonora Pozzi  1   2 , Paola Alberti  3   4
Affiliations

Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity

Eleonora Pozzi et al. Methods Mol Biol. 2022.

Abstract

Pharmacogenomics is a powerful tool to predict individual response to treatment, in order to personalize therapy, and it has been explored extensively in oncology practice. Not only efficacy on the malignant disease has been investigated but also the possibility to predict adverse effects due to drug administration. Chemotherapy-induced peripheral neurotoxicity (CIPN) is one of those. This potentially severe and long-lasting/permanent side effect of commonly administered anticancer drugs can severely impair quality of life (QoL) in a large cohort of long survival patients. So far, a pharmacogenomics-based approach in CIPN regard has been quite delusive, making a methodological improvement warranted in this field of interest: even the most refined genetic analysis cannot be effective if not applied correctly. Here we try to devise why it is so, suggesting how THE "bench-side" (pharmacogenomics) might benefit from and should cooperate with THE "bed-side" (clinimetrics), in order to make genetic profiling effective if applied to CIPN.

Keywords: Chemotherapy-induced peripheral neurotoxicity; Personalized medicine; Pharmacogenomics.

PubMed Disclaimer

References

    1. Syvänen AC (2005) Toward genome-wide SNP genotyping. Nat Genet 37(Suppl):S5–S10 - PubMed
    1. Velasco R, Alberti P, Bruna J et al (2019) Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment. J Peripher Nerv Syst 24(Suppl 2):S52–S62 - PubMed
    1. Islam B, Lustberg M, Staff NP et al (2019) Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment. J Peripher Nerv Syst 24(Suppl 2):S63–S73 - PubMed
    1. Tamburin S, Park SB, Alberti P et al (2019) Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment. J Peripher Nerv Syst 24(Suppl 2):S40–S51 - PubMed
    1. Alberti P (2019) Platinum-drugs induced peripheral neurotoxicity: clinical course and preclinical evidence. Expert Opin Drug Metab Toxicol 15(6):487–497 - PubMed

MeSH terms

Substances

LinkOut - more resources